Cargando…

Active surveillance for nonmuscle invasive bladder cancer

Nonmuscle invasive bladder cancer (NMIBC) is known to be a heterogeneous malignancy that requires varying treatment modalities and follow-up schedules. Low-grade Ta papillary tumors are categorized as low-risk NMIBC because of their favorable prognosis. There is an expanding movement that overdiagno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miyake, Makito, Fujimoto, Kiyohide, Hirao, Yoshihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Urological Association 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910757/ https://www.ncbi.nlm.nih.gov/pubmed/27326406 http://dx.doi.org/10.4111/icu.2016.57.S1.S4

Ejemplares similares

Diagnostics techniques in nonmuscle invasive bladder cancer
por: Soubra, Ayman, et al.
Publicado: (2015)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
por: Jokisch, Jan-Friedrich, et al.
Publicado: (2015)

Pretreatment assessment and perioperative nutritional interventions for patients with bladder cancer undergoing radical cystectomy
por: Miyake, Makito, et al.
Publicado: (2018)

The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer
por: Cahill, Ellen M., et al.
Publicado: (2022)

Advances in nonmuscle invasive bladder cancer
por: Konety, Badrinath R.
Publicado: (2015)

Nonmuscle invasive bladder cancer: a primer on immunotherapy
por: Maruf, Mahir, et al.
Publicado: (2016)

New therapies in nonmuscle invasive bladder cancer treatment
por: Rayn, Kareem N., et al.
Publicado: (2018)

Diagnostic approach for cancer cells in urine sediments by 5-aminolevulinic acid-based photodynamic detection in bladder cancer
por: Miyake, Makito, et al.
Publicado: (2014)

Emerging intravesical therapies for management of nonmuscle invasive bladder cancer
por: Tomaszewski, Jeffrey J, et al.
Publicado: (2010)

Additional oncological benefit of photodynamic diagnosis with blue light cystoscopy in transurethral resection for primary non‐muscle‐invasive bladder cancer: A comparative study from experienced institutes
por: Miyake, Makito, et al.
Publicado: (2023)

Optimal Treatment for Intermediate- and High-Risk, Nonmuscle-Invasive Bladder Cancer
por: van der Meijden, A.P.M.
Publicado: (2006)

Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral 5-Aminolevulinic Acid Decreases the Risk of Repeated Recurrence in Non-Muscle-Invasive Bladder Cancer: A Cumulative Incidence Analysis by the Person-Time Method
por: Miyake, Makito, et al.
Publicado: (2021)

Clinical significance of subepithelial growth patterns in non-muscle invasive bladder cancer
por: Miyake, Makito, et al.
Publicado: (2011)

Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model
por: Inoue, Takeshi, et al.
Publicado: (2013)

Depth of invasion to the bladder wall as a prognostic factor and its association with circulating cell-free DNA levels in patients with muscle-invasive bladder cancer
por: Iemura, Yusuke, et al.
Publicado: (2023)

The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer
por: Correa, Andres F., et al.
Publicado: (2015)

Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer
por: Lilge, Lothar, et al.
Publicado: (2020)

Inhibition of Heparanase Expression Results in Suppression of Invasion, Migration and Adhesion Abilities of Bladder Cancer Cells
por: Tatsumi, Yoshihiro, et al.
Publicado: (2020)

Photodynamic diagnosis of shed prostate cancer cells in voided urine treated with 5-aminolevulinic acid
por: Nakai, Yasushi, et al.
Publicado: (2014)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Metabolomics analysis reveals distinct profiles of nonmuscle‐invasive and muscle‐invasive bladder cancer
por: Sahu, Divya, et al.
Publicado: (2017)

Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy
por: Tomioka, Atsushi, et al.
Publicado: (2015)

Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer (Erratum)
por: Lilge, Lothar, et al.
Publicado: (2020)

The indispensable role of urinalysis for patients undergoing treatment for nonmuscle invasive bladder cancer
por: Di Gianfrancesco, Luca, et al.
Publicado: (2022)

Colony-stimulating factors detected in tumor cells and voided urine are potential prognostic markers for patients with muscle-invasive bladder cancer undergoing radical cystectomy
por: Morizawa, Yosuke, et al.
Publicado: (2018)

Effect of bladder distension on arginine vasopressin secretion in rats
por: Morizawa, Yosuke, et al.
Publicado: (2019)

CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer
por: Wettstein, Marian S., et al.
Publicado: (2015)

New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer
por: Ather, M Hammad, et al.
Publicado: (2015)

Overactive bladder induces transient hypertension
por: Torimoto, Kazumasa, et al.
Publicado: (2018)

Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model
por: Hori, Shunta, et al.
Publicado: (2017)

Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma
por: Miyake, Makito, et al.
Publicado: (2018)

Bladder cancer prospective cohort study on high‐risk non‐muscle invasive bladder cancer after photodynamic diagnosis‐assisted transurethral resection of the bladder tumor (BRIGHT study)
por: Kobayashi, Keita, et al.
Publicado: (2022)

Assessment of Pain Management, Acceptance of Illness, and Adjustment to Life with Cancer in Patients with Nonmuscle Invasive Bladder Cancer
por: Krajewski, Wojciech, et al.
Publicado: (2018)

Efficacy of pirarubicin for nonmuscle invasive bladder cancer: A protocol of systematic review and meta-analysis
por: Chen, Da-Yin, et al.
Publicado: (2020)

Erectile dysfunction in nonmuscle-invasive bladder cancer patients before and after transurethral resection (TUR) of bladder tumor in China
por: Guo, Peng, et al.
Publicado: (2021)

Optimal timing of ureteroscopic lithotripsy after the initial drainage treatment and risk factors for postoperative febrile urinary tract infection in patients with obstructive pyelonephritis: a retrospective study
por: Itami, Yoshitaka, et al.
Publicado: (2021)

5-Aminolevurinic acid inhibits the proliferation of bladder cancer cells by activating heme synthesis
por: Nakai, Yasushi, et al.
Publicado: (2022)

Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder
por: Lim, So Dug, et al.
Publicado: (2015)

MicroRNA-21 could be a molecular marker to predict the recurrence of nonmuscle invasive bladder cancer
por: Mitash, Nilay, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8boe1mne62t73ait96485gipfa